10x Genomics Partners with Brigham to Analyze Immune Signatures in 1,000 Autoimmune Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: Newsfilter
- Research Collaboration Initiated: 10x Genomics has partnered with Brigham and Women's Hospital to recruit 1,000 patients with rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis, aiming to uncover immune signatures that will provide scientific support for clinical decision-making.
- Technological Application Outlook: The study will utilize 10x's Chromium Flex single-cell assay to create detailed molecular maps of circulating immune cells, intending to identify key immune features associated with disease activity and treatment response, thereby enhancing the management of autoimmune diseases.
- Clinical Translation Potential: This collaboration aims not only to address the limitations of current clinical tests but also to establish a framework for future clinical reports that assist physicians in evaluating disease activity and formulating personalized treatment plans, promoting the application of personalized medicine in rheumatology.
- Industry Impact Enhancement: The CEO of 10x Genomics stated that this collaboration marks a significant step for the company in the field of autoimmune diseases, reflecting the potential of single-cell technology to improve the understanding and treatment of complex diseases, and is expected to drive further related research and collaborations.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on TXG
Wall Street analysts forecast TXG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TXG is 13.00 USD with a low forecast of 9.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 21.080
Low
9.00
Averages
13.00
High
18.00
Current: 21.080
Low
9.00
Averages
13.00
High
18.00
About TXG
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ark Invest Unveils 2026 Big Ideas, Forecasts 1.9% GDP Growth Boost
- Technological Acceleration: Ark Invest's report highlights that capital investment in disruptive innovation platforms could contribute 1.9 percentage points to annualized real GDP growth during this decade, emphasizing the potential of technologies like robotaxis and next-gen data centers.
- Strong ETF Performance: In 2025, Ark's Autonomous Technology & Robotics ETF and Space & Defense Innovation ETF achieved returns of 49.8% and 49.2%, respectively, showcasing the firm's ability to generate returns in emerging technology sectors.
- Bitcoin Holdings Surge: The report indicates that U.S. ETFs and public companies now hold 12% of total Bitcoin supply, with Bitcoin ETF balances up 19.7% and public company Bitcoin holdings up 73% in 2025, reflecting strong market demand for digital assets.
- Diverse Investment Opportunities: Ark Invest identifies several publicly traded companies, including Coinbase, Illumina, and Waymo, as key investment opportunities for the 2026 themes, indicating the firm's forward-looking approach to diversified investment strategies.
Continue Reading
Ark Invest Unveils 2026 Big Ideas, Focus on AI and Genomics
- AI Agents Theme: Ark Invest's first ARKmoji hints at agentic AI, with users divided on its meaning; the option 'AI Agent Takeover' received 37.5% support, indicating strong market interest in AI technologies that could impact stocks like Palantir.
- Genomics Potential: The second ARKmoji features a DNA helix, with 34.7% of votes for 'Molecular Diagnostics', highlighting investment opportunities in genomics, potentially benefiting related stocks like Crispr Therapeutics.
- Space Race Trend: The third ARKmoji depicts a rocket, with 55% of users selecting 'Reusable Rockets', reflecting enthusiasm for space technology investments, with holdings like Rocket Lab poised for growth.
- Robotics Development: The final ARKmoji shows a robot, with 59% voting for the 'Robotics' theme, indicating strong market interest in robotics technology, with Tesla's Optimus robot project likely to be a future growth driver.
Continue Reading